Evaluation of optimal psoriasis assessment tool (OPAT) incorporating both clinical and patient-reported outcomes for treatment of moderate-to-severe plaque psoriasis

被引：0
|
作者：
Leonardi, C. [2 ]
See, K. [1 ]
Burge, R. [1 ]
Gallo, G. [1 ]
McKean-Matthews, M. [3 ]
Goldblum, O. [1 ]
Wu, J. [4 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Cent Dermatol, St Louis, MO USA
[3] Syneos Hlth, Raleigh, NC USA
[4] Dermatol Res & Educ Fdn, Irvine, CA USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2019年 / 139卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
541
引用
收藏
页码：S93 / S93
页数：1
相关论文
共 50 条
  • [31] The benefits of adalimumab on clinical and patient-reported outcomes among moderate to severe psoriasis patients with comorbidities
    Kimball, Alexa
    Chen, Lei
    Mulani, Parvez
    Gupta, Shiraz
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB95 - AB95
  • [32] Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)
    Travaglini, Massimo
    Maul, Julia -Tatjana
    Kors, Christian
    Zaheri, Shirin
    Gerwien, Jens
    Mueller, Michaela
    Brnabic, Alan
    Sabatino, Silvia
    Schuster, Christopher
    Tsai, Tsen-Fang
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 2971 - 2983
  • [33] Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis
    Wong, Ian T. Y.
    Shojania, Kam
    Dutz, Jan
    Tsao, Nicole W.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 153 - 166
  • [34] Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis
    Scanlon, James V.
    Exter, Benjamin P.
    Steinberg, Michael
    Jarvis, Courtney I.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (09) : 1456 - 1465
  • [35] Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis
    Leman, J.
    Burden, A. D.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : 12 - 20
  • [36] Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium
    Carmona-Rocha, Elena
    Puig, Lluis
    IMMUNOTHERAPY, 2023, 15 (15) : 1209 - 1225
  • [37] Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
    Ren, Vicky
    Dao, Harry, Jr.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2013, 6 : 75 - 80
  • [38] A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis
    Roostaeyan, Omid
    Kivelevitch, Dario
    Menter, Alan
    IMMUNOTHERAPY, 2017, 9 (12) : 963 - 978
  • [39] A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
    Chiricozzi, Andrea
    Caposiena, Dante
    Garofalo, Virginia
    Cannizzaro, Maria Vittoria
    Chimenti, Sergio
    Saraceno, Rosita
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (03) : 237 - 249
  • [40] Patient-reported outcomes and physician's satisfaction after 28 weeks of treatment with tildrakizumab in moderate-to-severe plaque psoriasis: interim analysis of the noninterventional study TILOT
    Tsianakas, A.
    Ostendorf, R.
    Diemert, S.
    Hinz, T.
    Pierchalla, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E40 - E40
12345